MCID: SPC010
MIFTS: 52

Speech and Communication Disorders

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

MalaCards integrated aliases for Speech and Communication Disorders:

Name: Speech and Communication Disorders 41 43
Communication Disorder 41 12 15
Language Disorders 55 44 73
Language Disorder 41 12 15
Communication Disorders 55 44
Speech and Language Disorder 73
Speech Language Disorder 41
Communication Impairment 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
ICD10 33 F80.9
NCIt 50 C2958 C97155

Summaries for Speech and Communication Disorders

MedlinePlus : 43 Many disorders can affect our ability to speak and communicate. They range from saying sounds incorrectly to being completely unable to speak or understand speech. Causes include Hearing disorders and deafness Voice problems, such as dysphonia or those caused by cleft lip or palate Speech problems like stuttering Developmental disabilities Learning disorders Autism spectrum disorder Brain injury Stroke Some speech and communication problems may be genetic. Often, no one knows the causes. By first grade, about 5 percent of children have noticeable speech disorders. Speech and language therapy can help. NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to expressive language disorder and stuttering, and has symptoms including lethargy, neurobehavioral manifestations and aprosodia. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease Pathway. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and tongue, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A specific developmental disorder that involves specific developmental disorders of speech and language.

Wikipedia : 76 A communication disorder is any disorder that affects an individual\'s ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Related Disease Score Top Affiliating Genes
1 expressive language disorder 32.3 FOXP2 PSEN1 TARDBP
2 stuttering 32.0 CNTNAP2 FOXP2 GNPTG
3 speech disorder 31.6 CNTNAP2 FOXP2 GNPTG GRIN2A GRN
4 childhood apraxia of speech 11.0 CNTNAP2 FOXP2
5 posterior cortical atrophy 11.0 APOE MAPT
6 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.0 GRN MAPT
7 alzheimer disease 4 10.9 APOE PSEN1
8 amusia 10.9 GRN PLG
9 prosopagnosia 10.9 GRN PSEN1
10 phonagnosia 10.9 GRN PSEN1 TARDBP
11 associative agnosia 10.9 GRN PSEN1 TARDBP
12 writing disorder 10.9 GRN PSEN1 TARDBP
13 alexia 10.9 APOE PSEN1 TARDBP
14 familial idiopathic basal ganglia calcification 10.9 APOE MAPT PSEN1
15 cerebral amyloid angiopathy, cst3-related 10.9 APOE MAPT PSEN1
16 cluttering 10.8
17 perry syndrome 10.8 C9orf72 GRN TARDBP
18 inclusion body myositis 10.8 APOE MAPT TARDBP
19 vascular dementia 10.8 APOE MAPT PSEN1
20 mixed receptive-expressive language disorder 10.8
21 autoimmune encephalitis 10.8 CNTNAP2 TRPV1
22 anosognosia 10.7 GRN SMUG1
23 articulation disorder 10.7 CNTNAP2 FOXP2 GNPTG
24 pulmonary artery leiomyosarcoma 10.7 PLG SMUG1
25 simultanagnosia 10.7 APOE MAPT SMUG1
26 echolalia 10.7 CBS GRN MAPT PSEN1
27 amyotrophic lateral sclerosis 18 10.7 C9orf72 TARDBP
28 progressive non-fluent aphasia 10.7 C9orf72 GRN MAPT PSEN1
29 behavioral variant of frontotemporal dementia 10.7 C9orf72 GRN MAPT PSEN1
30 arteries, anomalies of 10.7 APOE PLG TRPV1
31 mutism 10.7 CNTNAP2 GRN
32 heart cancer 10.7 APOE SMUG1
33 pervasive developmental disorder 10.6 CNTNAP2 FOXP2 MECP2
34 benign epilepsy with centrotemporal spikes 10.6 CNTNAP2 FOXP2 GRIN2A
35 motor neuron disease 10.6 C9orf72 GRN MAPT TARDBP
36 meniere disease 10.6
37 usher syndrome 10.6
38 acoustic neuroma 10.6
39 agnosia 10.6
40 reading disorder 10.6 CNTNAP2 FOXP2 KIAA0319 PSEN1
41 pick disease of brain 10.6 APOE GRN MAPT PSEN1 TARDBP
42 postencephalitic parkinson disease 10.6 MAPT TARDBP
43 alzheimer disease 2 10.5 APOE MAPT PSEN1 SMUG1
44 agraphia 10.5 CBS GRN MAPT PSEN1 TARDBP
45 ideomotor apraxia 10.5 CBS GRN MAPT PSEN1 TARDBP
46 apraxia 10.5 C9orf72 FOXP2 GRN MAPT PSEN1
47 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 10.5 C9orf72 CBS GRN PSEN1 TARDBP
48 gait apraxia 10.5 APOE CBS GRN MECP2 PSEN1
49 kluver-bucy syndrome 10.4 MAPT PSEN1
50 amyotrophic lateral sclerosis 1 10.4 C9orf72 GRN MAPT PSEN1 TARDBP

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


lethargy, neurobehavioral manifestations, aprosodia, other symbolic dysfunction

MGI Mouse Phenotypes related to Speech and Communication Disorders:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 MAPT C9orf72 MECP2 CNTNAP2 PLG PSEN1
2 behavior/neurological MP:0005386 10.14 APOE MAPT C9orf72 MECP2 CNTNAP2 GRIN2A
3 immune system MP:0005387 10.02 APOE MAPT C9orf72 CMIP MECP2 PLG
4 nervous system MP:0003631 9.97 MAPT C9orf72 MECP2 CMIP CNTNAP2 PLG
5 integument MP:0010771 9.86 APOE MAPT MECP2 PLG CNTNAP2 GRIN2A
6 no phenotypic analysis MP:0003012 9.5 APOE MAPT C9orf72 MECP2 GRN TARDBP
7 taste/olfaction MP:0005394 8.92 APOE MAPT CNTNAP2 TRPV1

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
3
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
4
Haloperidol Approved Phase 4 52-86-8 3559
5
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
8
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
9
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
12
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
13 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Dopamine agonists Phase 4,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
21 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
22 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Not Applicable
23 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
24 adderall Phase 4,Phase 2
25 Central Nervous System Stimulants Phase 4,Phase 2,Not Applicable
26 Dopamine Uptake Inhibitors Phase 4,Phase 2
27 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
28 Antiemetics Phase 4,Phase 3
29 Antipsychotic Agents Phase 4,Phase 3,Phase 2
30 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 decanoic acid Phase 4
32 Dopamine Antagonists Phase 4,Phase 3,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
34 Haloperidol decanoate Phase 4
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Serotonin Agents Phase 4,Phase 3
37 Serotonin Uptake Inhibitors Phase 4
38 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
41 Adrenergic Agents Phase 4,Not Applicable
42 Adrenergic Agonists Phase 4,Not Applicable
43 Adrenergic alpha-2 Receptor Agonists Phase 4
44 Adrenergic alpha-Agonists Phase 4,Not Applicable
45 Antihypertensive Agents Phase 4
46 Atomoxetine Hydrochloride Phase 4
47 Antidepressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
48 Antidepressive Agents, Second-Generation Phase 4
49 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
50 Radiopharmaceuticals Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 675)
# Name Status NCT ID Phase Drugs
1 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4 Levodopa
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Omega 3/6 Fatty Acids for Reading in Children Completed NCT02557477 Phase 4
4 Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke Completed NCT02473432 Phase 4
5 Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment Completed NCT00191555 Phase 4 olanzapine;haloperidol
6 Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease Completed NCT00469456 Phase 4 Memantine;placebo
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
9 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
10 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4 Methylphenidate;Mixed Salt Amphetamine;Atomoxetine;Guanfacine
11 Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Completed NCT00607919 Phase 4 Atomoxetine;Placebo
12 Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia Completed NCT00716274 Phase 4 Atomoxetine;Placebo
13 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
14 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
15 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
16 Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Completed NCT00191048 Phase 4 Atomoxetine
17 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
18 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
19 Drug to Prevent Pneumonia in the Tube Fed Terminated NCT02358642 Phase 4 Angiotensin converting enzyme inhibitor (Lisinopril);Placebo
20 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
21 Randomized Clinical Trial of Phonological Interventions Unknown status NCT00818428 Phase 2, Phase 3
22 Feasibility of Omega-3 Supplementation for Children With Language Impairments Unknown status NCT01640106 Phase 3
23 Effectiveness of Early Parent-Based Language Intervention Unknown status NCT00625261 Phase 3
24 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
25 Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities Unknown status NCT00246792 Phase 2, Phase 3
26 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
27 Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea Completed NCT00660777 Phase 3
28 A Comparison of Language Intervention Programs Completed NCT00033150 Phase 3
29 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
30 Balance Training in Parkinson's Disease Using Cues Completed NCT01960985 Phase 3
31 Acute Otitis Media: Adjuvant Therapy to Improve Outcome Completed NCT00000363 Phase 3 Antihistamine;Corticosteroid
32 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children Completed NCT01044030 Phase 3 Xylitol syrup;Placebo
33 Sudden Deafness Treatment Trial Completed NCT00097448 Phase 3 prednisone;methylprednisolone sodium succinate
34 Secretin for the Treatment of Autism Completed NCT00065962 Phase 3 secretin, synthetic porcine;secretin, biologically derived porcine
35 Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed NCT01028053 Phase 3 Flutemetamol (18F) Injection
36 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
37 A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children Completed NCT00254930 Phase 3 risperidone
38 A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Completed NCT00830154 Phase 2, Phase 3 pagoclone
39 Reading Problems in Children Living in Urban Areas Completed NCT00065832 Phase 3
40 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
41 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
42 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
43 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
44 Tinnitus Retraining Therapy Trial Completed NCT01177137 Phase 3
45 Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Recruiting NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
46 Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
47 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
48 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
49 Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children Recruiting NCT03159104 Phase 3 Tenoten for children;Placebo
50 Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media Active, not recruiting NCT02567825 Phase 3

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

41
Brain, Testes, Tongue, Cortex, Bone, Liver, Eye

Publications for Speech and Communication Disorders

Articles related to Speech and Communication Disorders:

(show all 38)
# Title Authors Year
1
A Pediatrician's Guide to Communication Disorders Secondary to Cleft Lip/Palate. ( 29173718 )
2018
2
Cleft Lip and Palate: Demographic Patterns and the Associated Communication Disorders. ( 29023294 )
2017
3
Social (pragmatic) communication disorders and autism spectrum disorder. ( 26699538 )
2016
4
Poststroke Communication Disorders and Dysphagia. ( 26522904 )
2015
5
Autism, Language Disorder, and Social (Pragmatic) Communication Disorder: DSM-V and Differential Diagnoses. ( 26232465 )
2015
6
Phenotype-genotype discordance in congenital malformations with communication disorders resembling trisomy 18 (Edwards syndrome). ( 24478819 )
2014
7
Association between AVPR1A, DRD2, and ASPM and endophenotypes of communication disorders. ( 24849541 )
2014
8
Observational assessment of communication disorders in vascular dementia patients with right hemisphere damage. ( 25323958 )
2014
9
Traumatic brain injury in veterans of the wars in Iraq and Afghanistan: communication disorders stratified by severity of brain injury. ( 24131337 )
2013
10
Social communication disorder outside autism? A diagnostic classification approach to delineating pragmatic language impairment, high functioning autism and specific language impairment. ( 23639107 )
2013
11
Practitioner Review: Social (pragmatic) communication disorder conceptualization, evidence and clinical implications. ( 24117874 )
2013
12
Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders. ( 23730274 )
2013
13
Nature and onset of communication disorder in pediatrics with HIV. ( 22542284 )
2012
14
Communication disorders related to cleft palate, craniofacial anomalies, and velopharyngeal dysfunction. ( 21948635 )
2011
15
An audiological communication disorder? ( 21586253 )
2011
16
Evaluation sensitivity as a moderator of communication disorder in schizophrenia. ( 19379529 )
2009
17
Attention deficit hyperactivity disorder and concomitant communicative disorders. ( 15359365 )
2004
18
Work integration issues go beyond the nature of the communication disorder. ( 12036151 )
2002
19
A case-control study of EAS child and parental temperaments in selectively mute children with and without a co-morbid communication disorder. ( 12470308 )
2002
20
Profiles of communication disorder in children with velocardiofacial syndrome: comparison to children with Down syndrome. ( 11339384 )
2001
21
"Pure word deafness": implications for assessment and management in communication disorder--a report of two cases. ( 10489017 )
1999
22
Re: Ward, S., 1999, an investigation into the effectiveness of an early intervention method for delayed language development in young children. International Journal for Language & Communication Disorder, 34, 243-246. ( 10884911 )
1999
23
Re: Ward, S., 1999 an investigation into the effectiveness of an early intervention method for the delayed language development in young children. International Journal of Language & Communication Disorder, 34, 243-264. ( 10884913 )
1999
24
Re: Ward, S., 1999 an investigation into the effectiveness of an early intervention method for delayed language development in young children. International Journal of Language & Communication Disorder, 34,243-246. ( 10884912 )
1999
25
Evaluation of a child with communication disorder. ( 10744867 )
1999
26
Cognitive-communicative disorders of right cerebrovascular accident patients and reimbursement for treatment. ( 10597115 )
1999
27
Learning disabilities existing concomitantly with communication disorder. ( 9146094 )
1997
28
Thought disorder or communication disorder. Linguistic science provides a new approach. ( 7788117 )
1995
29
Thought disorder or communication disorder. ( 7663838 )
1995
30
Thought disorder or communication disorder. ( 7663837 )
1995
31
Formal communication disorder. Sign language in deaf people with schizophrenia. ( 7881785 )
1994
32
Autism AKA communication disorder. ( 7679094 )
1993
33
Communication disorder in renaissance Italy: an unreported case analysis by Hieronymus Mercurialis (1530-1606). ( 2184171 )
1990
34
Prevalence, type, and correlates of psychiatric diagnoses in 200 children with communication disorder. ( 7320202 )
1981
35
Selective involvement of the auditory-verbal modality in an acquired communication disorder: benefit from sign language therapy. ( 7237115 )
1981
36
The communication disorder in dialysis dementia: a case report. ( 7407554 )
1980
37
The pediatrician and the child with a communication disorder. "Semiverbality" in children. ( 4761178 )
1973
38
THE PREVENTION OF COMMUNICATION DISORDER BY THE USE OF A SIMPLIFIED ALPHABET. ( 14141732 )
1964

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.7 APOE CNTNAP2 GRIN2A MAPT MECP2 PSEN1
2 10.79 APOE MAPT PSEN1

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.62 C9orf72 CNTNAP2 MAPT PSEN1
2 neuronal cell body GO:0043025 9.55 APOE CNTNAP2 MAPT PSEN1 TRPV1
3 growth cone GO:0030426 9.54 C9orf72 MAPT PSEN1
4 axolemma GO:0030673 9.26 CNTNAP2 MAPT
5 dendrite GO:0030425 9.1 APOE C9orf72 CNTNAP2 MAPT PSEN1 TRPV1
6 main axon GO:0044304 8.96 C9orf72 MAPT

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.86 CNTNAP2 GRIN2A MECP2 PSEN1
2 negative regulation of gene expression GO:0010629 9.81 APOE MAPT MECP2 TARDBP
3 cellular calcium ion homeostasis GO:0006874 9.77 APOE ATP2C2 PSEN1
4 post-embryonic development GO:0009791 9.71 FOXP2 MECP2 PSEN1
5 excitatory postsynaptic potential GO:0060079 9.7 GRIN2A MECP2 TRPV1
6 negative regulation of protein phosphorylation GO:0001933 9.67 C9orf72 PSEN1 TARDBP
7 cerebral cortex development GO:0021987 9.65 CNTNAP2 FOXP2 PSEN1
8 calcium ion transport GO:0006816 9.62 ATP2C2 GRIN2A PSEN1 TRPV1
9 learning GO:0007612 9.61 CNTNAP2 GRIN2A MECP2
10 startle response GO:0001964 9.6 GRIN2A MECP2
11 microglial cell activation GO:0001774 9.58 MAPT TRPV1
12 locomotion GO:0040011 9.58 GRIN2A PSEN1
13 stress granule assembly GO:0034063 9.57 C9orf72 MAPT
14 amyloid precursor protein metabolic process GO:0042982 9.55 APOE PSEN1
15 sensory perception of pain GO:0019233 9.54 GRIN2A MECP2 TRPV1
16 astrocyte activation GO:0048143 9.46 MAPT PSEN1
17 calcium ion transmembrane transport GO:0070588 9.46 ATP2C2 GRIN2A PSEN1 TRPV1
18 vocal learning GO:0042297 9.4 CNTNAP2 FOXP2
19 positive regulation of amyloid fibril formation GO:1905908 9.26 APOE PSEN1
20 memory GO:0007613 9.26 GRIN2A MAPT MECP2 PSEN1
21 regulation of synaptic plasticity GO:0048167 8.92 GRIN2A MAPT MECP2 PSEN1

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 APOE CBS FOXP2 MAPT TARDBP TRPV1
2 apolipoprotein binding GO:0034185 9.26 MAPT PLG
3 calcium channel activity GO:0005262 9.13 GRIN2A PSEN1 TRPV1
4 lipoprotein particle binding GO:0071813 8.62 APOE MAPT
5 protein binding GO:0005515 10.09 APOE ATP2C2 C9orf72 CBS CMIP CNTNAP2

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....